



A CSR Initiative



# JAGSONPAL PHARMACEUTICALS LIMITED

Corporate Office: Nimai Tower, 3<sup>rd</sup> Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India)

October 23, 2024

The Department of Corporate Services- Listing <b>BSE Ltd,</b> Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 <b>Scrip Code: 507789</b>	The Department of Corporate Services- Listing <b>National Stock Exchange of India Ltd</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 <b>Symbol: JAGSNPHARM</b>
---	--

## **Subject: Outcome of Board Meeting held on October 23, 2024 & Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015**

Dear Sir/ Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the following:

1. Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2024.
2. Sub-division/ split of the existing Equity Shares of the Company, such that each Equity Share having face value of Rs. 5/- (Rupees Five only) each fully paid-up, be sub-divided/split into such number of Equity Shares having face value of Rs. 2 each fully paid-up, subject to the approval of Equity Shareholders of the Company through Postal Ballot.

The Record Date for sub-division/split of existing Equity Shares shall be decided after taking aforesaid approval of the Equity Shareholders of the Company.

3. Consequent Alteration of the Capital Clause (Clause V) of the Memorandum of Association and Article 4 of the Company on account of aforesaid sub-division/split of existing Equity Shares “

The Company will shortly be seeking approval of equity shareholders through postal ballot for the Sub-division/Split of shares and for consequent amendment to the Memorandum of Association/ Articles of Association of the Company.

Ph.: +91 124 4406710; E-mail: [cs@jagsonpal.com](mailto:cs@jagsonpal.com); Website: [www.jagsonpal.com](http://www.jagsonpal.com)

CIN NO. L74899DL1978PLC009181

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110049 (India)



A CSR Initiative



The detailed disclosure for aforesaid point no. 2 as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-I/P/CIR/2023/123 dated July 13, 2023 is enclosed as Annexure I.

The Board Meeting commenced at 04:50 p.m. and concluded at 5:40 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

**Abhishek Joshi**

**Company Secretary & Compliance Officer**



A CSR Initiative



## Annexure – I

## Disclosure under Regulation 30 of SEBI Listing Regulations

Sr. No.	Particulars	Disclosure				
1.	Split Ratio	Existing Equity Share having face value of Rs. 5/- each fully paid up, will be sub-divided/split into such number of Equity Shares having face value of Rs. 2 each fully paid up				
2.	Rationale behind the split	To enhance liquidity of the Company's equity shares and to facilitate participation of small investors by making equity shares of the Company more affordable to invest				
3.	Pre and Post share capital – authorized, paid up and subscribed		Pre Sub-Division/Split		Post Sub-Division/Split	
		Particulars	No. of Equity Shares	Face Value (Rs.)	No. of Equity Shares	Face Value (Rs.)
		<b>Authorized Equity Share Capital</b>				
		Equity shares	3,00,00,000	5	7,50,00,000	2
		Unclassified shares	2,00,00,000	5	5,00,00,000	2
		<b>Issued, Subscribed and Paid-up Equity Share Capital</b>				
		Equity shares*	2,64,84,611	5	66,211,528	2
		*Based on paid up equity capital as on date and subject to change depending on paid up equity capital as on record date.				
4.	Expected time of Completion	Within 3(three) months from the date of approval of Equity Shareholder of the Company				
5.	Class of Shares which are sub-divided	Equity Shares				
6.	Number of Shares of each class pre and post split	Refer details stated at point no. 2 and 3				



A CSR Initiative



JAGSONPAL

7.	Number of shareholders who did not get any shares in consolidation and their pre-consolidation shareholding	Not Applicable
----	---	----------------